Solid Biosciences (SLDB) AI Stock Analysis

• Market Cap: $481.49M
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: N/A
• EPS Growth: 17.88%
• Country: US
• Employees: 100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 77,910,240
• 10 Day Avg. Volume: 1,069,520
• 30 Day Avg. Volume: 1,076,061
• PEG Ratio: 0.04
• Price to Book (P/B): 1.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.62
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -560.40
• Enterprise Value/Ebitda: -2.69
• 1Y Price Target: $16.75
• Price Target Upside: 166.30% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -2.04
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $6.50 ▲(3.34% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is held down primarily by very weak fundamentals—zero TTM revenue, widening losses, and significant ongoing cash burn—despite a relatively low-debt balance sheet. Technicals are moderately supportive with neutral-to-positive momentum, but valuation remains difficult to justify on earnings due to the negative P/E and no dividend.

Positive Factors

Precision genetic-medicine focus

A pipeline centered on gene and genetic-medicine approaches targets root causes of DMD rather than symptoms. This strategic focus aligns with durable structural demand for disease-modifying therapies, creating high clinical value and long-term commercial optionality if clinical/regulatory success is achieved.

Low financial leverage

Relatively low debt versus equity provides financial flexibility versus peers in a cash-intensive development stage. Lower leverage reduces near-term solvency risk, preserving optionality to fund trials or seek partnerships without immediate pressure from high interest obligations, supporting sustained R&D investment.

Positive SGT-003 interim data

Interim clinical signals and planned FDA engagement represent a structural inflection point: favorable biomarker and safety data can materially reduce development and regulatory risk, accelerate timelines, enhance partner interest, and improve odds of eventual commercial revenue and durable franchise value.

Negative Factors

No revenue and widening losses

A sustained absence of product revenue and growing operating losses indicate the company remains pre-commercial and value depends entirely on trial outcomes. Persistent negative margins erode equity over time and mean long-term viability hinges on successful commercialization or transformational partnerships.

Heavy and accelerating cash burn

Large negative operating and free cash flows that have worsened year-over-year create an ongoing need for external capital. Recurrent fundraising risks dilution, can delay development programs, and places strategic pressure on management to secure partnerships or approvals to stabilize funding sources.

Funding- and execution-dependent model

The business model depends on successful clinical outcomes, regulatory approvals, partner deals, and scalable gene-therapy manufacturing. These structural execution risks — manufacturing complexity, regulatory hurdles, and partner dependence — can materially delay or derail value creation absent consistent capital and proven operations.

Solid Biosciences Business Overview & Revenue Model

Company Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Solid Biosciences generates revenue primarily through the development and potential commercialization of its gene therapy programs targeting Duchenne muscular dystrophy. The company's revenue streams include collaborations and partnerships with other biotechnology and pharmaceutical companies, grants, and potential milestone and royalty payments from licensing agreements. Additionally, Solid Biosciences may derive future revenues from the successful approval and commercialization of its proprietary therapies, which would include sales revenue from products reaching the market. The company's focus on innovative treatments and strategic alliances are key factors contributing to its financial prospects.

Solid Biosciences Financial Statement Overview

Summary

Financials reflect a development-stage biotech profile: TTM revenue is $0 with large and widening losses (EBIT -$169.7M; net loss -$167.1M) and heavy cash burn (TTM FCF -$133.2M). The key offset is comparatively modest leverage (debt $21.9M vs. equity $217.9M), but negative returns and ongoing burn remain the dominant risk.

Income Statement

Operating performance remains very weak. TTM (Trailing-Twelve-Months) revenue is $0 and losses are substantial (EBIT of -$169.7M and net income of -$167.1M), with deeply negative margins. Losses have also widened versus 2024 (net loss -$124.7M), indicating profitability is not yet stabilizing. A historical revenue base existed in 2021–2022, but revenue has since fallen to $0, highlighting commercialization and/or milestone volatility risk.

Balance Sheet

The balance sheet looks comparatively more resilient than the income statement, with low leverage. Total debt is $21.9M against $217.9M of equity in TTM (Trailing-Twelve-Months), implying modest balance-sheet risk and improvement versus 2023–2024 debt-to-equity levels. However, returns remain very negative (TTM return on equity around -0.74), reflecting persistent losses that can continue to pressure equity over time despite the current low debt load.

Cash Flow

Cash burn is heavy and ongoing. TTM (Trailing-Twelve-Months) operating cash flow is -$132.4M and free cash flow is -$133.2M, worse than 2024 (about -$100.7M free cash flow), suggesting an accelerating cash requirement. Free cash flow improved on a growth basis in TTM, but it remains meaningfully negative, and cash flow roughly tracks net losses—supporting the view that the business is still funding operations primarily through external capital rather than self-sustaining cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	8.09M	13.62M	0.00
Gross Profit	-793.00K	-2.46M	-2.58M	8.09M	13.62M	-3.92M
EBITDA	-165.28M	-121.90M	-93.43M	-96.87M	-69.29M	-84.37M
Net Income	-167.13M	-124.70M	-96.02M	-85.98M	-72.19M	-88.29M
Balance Sheet
Total Assets	273.91M	188.66M	164.94M	260.25M	232.38M	171.17M
Cash, Cash Equivalents and Short-Term Investments	236.14M	148.92M	123.64M	213.72M	207.78M	154.74M
Total Debt	21.94M	24.18M	26.27M	28.55M	2.06M	5.15M
Total Liabilities	55.97M	51.42M	38.46M	48.59M	24.17M	39.08M
Stockholders Equity	217.95M	137.25M	126.48M	211.67M	208.21M	132.09M
Cash Flow
Free Cash Flow	-133.17M	-100.67M	-95.69M	-100.99M	-79.05M	-57.50M
Operating Cash Flow	-132.38M	-100.01M	-94.18M	-97.98M	-77.76M	-56.60M
Investing Cash Flow	-66.90M	-16.09M	9.69M	59.16M	-91.09M	6.60M
Financing Cash Flow	196.24M	122.44M	3.12M	74.83M	134.99M	128.70M

Solid Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLDB, the sentiment is Positive. The current price of 6.29 is above the 20-day moving average (MA) of 6.27, above the 50-day MA of 5.98, and above the 200-day MA of 5.41, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 53.03 is Neutral, neither overbought nor oversold. The STOCH value of 74.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLDB.

Solid Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLUE	75 Outperform	$1.46B	59.23	9.28%	―	1112.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AUTL	51 Neutral	$484.38M	-2.09	-60.52%	―	407.86%	30.35%
KRRO	49 Neutral	$112.35M	-1.29	-63.46%	―	―	21.61%
ADCT	48 Neutral	$543.82M	-2.95	―	―	6.35%	39.57%
SLDB	47 Neutral	$481.49M	-2.53	-86.83%	―	―	17.88%

Solid Biosciences Corporate Events

Solid Biosciences Reports Positive Interim Data on SGT-003

On November 3, 2025, Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, highlighting the safety, tolerability, and efficacy of SGT-003 in treating Duchenne muscular dystrophy. The trial, which has dosed 23 participants across multiple countries, showed strong correlations between SGT-003 microdystrophin therapy and improvements in muscle integrity biomarkers, suggesting a potential breakthrough in gene therapy for Duchenne. The company plans to discuss potential accelerated approval pathways with the FDA in 2026, while also progressing with its Phase 3 IMPACT DUCHENNE trial and other clinical programs.

The most recent analyst rating on (SLDB) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Solid Biosciences stock, see the SLDB Stock Forecast page.